Статья
БЕТА-АДРЕНОБЛОКАТОРЫ И АГРЕГАЦИЯ ТРОМБОЦИТОВ. КАРВЕДИЛОЛ
Рассмотрена эволюция подходов к изучению влияния бета-блокаторов на агрегацию тромбоцитов. Представлена современная концепция, интерпретирующая антиагрегационный потенциал бета-блокаторов с позиций физико-химических свойств препаратов, таких как гидрофобность, дипольный момент, молекулярная масса. Обобщены данные исследований по влиянию карведилола на агрегацию тромбоцитов.
1. Задионченко В.С., Яковлева М.С., Шехян Г.Г., Миронова М.А. Применение карведилола в комплексной терапии больных инфарктом миокарда с зубцом Q. Тер арх 2005;(8):14-9.
2. Новиков Т.А., Зарудий Ф.А., Закирова А.Н. Влияние небиволола на агрегацию тромбоцитов и противосвертывающую систему. Кардиология 2003;(7):70-6
3. Преображенский Д.В., Сидоренко Б.А., Дедова И.С., Тарыкина Е.В. Блокаторыβ-адренорецепторов в лечении сердечно-сосудистых заболеваний: место карведилола. Кардиология 2006;(12): 63-72
4. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71– 86
5. Bartsch W, Sponer G, Strein K, et al. Pharmacological characteristics of the stereoisomers of carvedilol. Eur J Clin Pharmacol 1990; 38 Suppl 2:S104-7.
6. Clappers N, Brouwer MA, Verheugt F. Antiplatelet treatment for coronary heart disease. Heart 2007; 93(2):258-65
7. Cheng H.Y., Randall C.S., Holl W.W. et al. Carvedilol-liposome interaction: evidence for strong association with hydrophobic region of lipid bilayers. Biochim Biophys Acta 1996;1284(1):20-8
8. Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drugs Rev 2001; 19(2):152-71
9. Dash D, Rao K. Effect of propranolol on platelet signal transduction. Biochem J 1995;309:99-104
10. Falciani M., Rinaldi B., D’Agostino B. et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol 2001;38:922-9
11. Feuerstein G, Yue T-L, Ma X, et al. Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998;41:17–24
12. Frishman W.H., Weksler B., Christodoulou J.P. et al. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation 1974; 50:887- 96
13. Fuster V., Badimon L., Badimon J.J. et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:310–8
14. Gasser JA, Betterridge DJ. Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers. J Сardiovasc Pharmacol 1991; 18 Suppl 4:S29-34
15. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378–84
16. Girke S, Mohr K, Schrape S. Comparison between the cationic amphiphilic drugs to affect phospholipid membranes and to depress cardiac function. Biochem Pharmacol 1989;38:2487-96
17. Hansen K.W., Klysner R., Geisler A. et al. Platelet aggregation and betablockers. Lancet 1982; 1(8265):224-5
18. Kalimowski L., Dobrucci L.W., Szczepanska-Konkel M. et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypetensive action. Circulation 2003; 107(21):2747-52.
19. Kerry R, Scrutton MC, Wallis RB. Beta-adrenoceptor antagonists and human platelets: relation of effects to lipid solubility. Biochem Pharmacol 1984; 33(16):2615-22
20. Knight CJ, Panesar M, Wilson DJ, et al. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation 1997; 95(1):125-32
21. Kurosaki K, Ikeda U, Maeda Y, et al. Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes. J Molecular and Cellular Cardiology 2000;32(2):333-9
22. Nosál’ R, Jančinová V, Ondriaš K, et al. The interaction of beta-adrenoceptor blocking drugs with platelet aggregation, calcium displacement and fluidization of the membrane. Biochim Biophys Acta 1985; 821:217-28
23. Pečivová J, Mačičková T, Lojek A. In vitro effect of carvedilol on professional phagocytes. Pharmacology 2007;79:86-92
24. Petrikova M., Jančinová V., Nosál’ R. et al. Carvedilol--a beta-blocker with considerable antiaggregatory effect on human blood platelets. Bratisl Lek Listy 2005;106(1):20-5
25. Punda A., Polić S., Rumboldt Z. et al. Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial. Croat Med J 2005;46(2):219-24
26. Butler S, Wang R, Wunder SL, Cheng HY, Randall CS. Perturbing effects of carvedilol on a model membrane system: role of lipophilicity and chemical structure. Biophys Chem 2006;119:307-15
27. Weksler B, Gillik M, Pink J. Effect of propranolol on platelet function. Blood 1977; 49:185-96
28. Winther K, Gleerup G, Hedner T. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and betaadrenergic receptor blockers. J Cardiovasc Pharmacol 1991; 18 Suppl 9:S41-4.
29. Winther K., Knudsen J.B., Gormsen J. et al. Effect of metoprolol and propranolol on platelet aggregation and cAMP level in hypertensive patients. Eur J Clin Pharmacol 1986;29:561-4
30. Winther K, Trap-Jensen J. Effects of three beta-blockers with different pharmacodynamic properties on platelet aggregation and platelet and plasma cyclic AMP. Eur J Clin Pharmacol 1988; 35:17-20